Nesiritide and Renal Function After the Total Artificial Heart

• Status: Terminated
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The prevalence of renal dysfunction after implantation of the artificial heart is high. The infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total artificial heart (TAH) improves renal function in a sustained manner. The renal protective and hormone-modulating effects of nesiritide may be enhanced with ventriculectomy compared to heart failure surgery that leaves the native myocardium intact. The goal of this project is to determine the renal protective effects of nesiritide after implantation of a mechanical device.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Treatments: Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Implanted with a total artificial heart (CardioWest) or Left ventricular assist device (HeartMate II)

• Age > 18 years

Exclusion Criteria:

• Previous calcineurin inhibitor (CNI) exposure

• Hemodialysis prior to device implant